Resurge Therapeutics Launches First-in-Human Clinical Study for Innovative BPH Treatment in the Dominican Republic
For Immediate Release
Miami, Florida - December 8, 2024
Resurge Therapeutics, Inc., a pioneering company in minimally invasive local drug delivery solutions for urology, launched its first-in-human clinical study for a novel Benign Prostatic Hyperplasia (BPH) treatment in the Dominican Republic. This groundbreaking study marks a significant milestone in the company’s mission to solve unmet problems in urology and improve the quality of life for millions of men worldwide.
Study Objectives and Significance
The primary objective of this first-in-human study is to evaluate the safety and initial efficacy of Resurge Therapeutics’ innovative local drug delivery system for BPH treatment. BPH, a condition affecting approximately 40 million men in the US alone, causes uncomfortable urinary symptoms and can lead to serious complications if left untreated.
This study represents a pivotal moment in Resurge Therapeutics' quest to revolutionize BPH treatment. The company's approach aims to provide a minimally invasive solution that could offer rapid symptom relief without the side effects of current systemic medications.
Innovative Therapy
Resurge Therapeutics’ proprietary technology focuses on innovative local drug delivery designed to treat BPH more efficiently than traditional oral medications. This approach can potentially minimize systemic side effects while maximizing therapeutic impact.
Resurge Therapeutic's technology is built on years of drug delivery and urology expertise. The company believes that this study will demonstrate the potential of its innovative approach to transform BPH treatment, offering hope to millions of men suffering from this condition.
Collaboration with Local Health Authorities and bioaccess®
The study is being conducted in collaboration with leading medical institutions in the Dominican Republic and has received all necessary approvals from local health authorities. Resurge Therapeutics has partnered with bioaccess®, the only Medtech contract research organization (CRO) in Latin America, to ensure the study’s smooth execution and compliance with international standards.
Resurge Therapeutics is excited to work with bioaccess® and the talented medical professionals in the Dominican Republic. bioaccess®'s expertise and the country’s supportive clinical research environment make it an ideal location for this critical study.
Expected Impact on Patient Care
If successful, this study could pave the way for a new treatment option that significantly improves the standard of care for BPH patients. The potential benefits include faster symptom relief, reduced side effects, and improved quality of life for millions of men worldwide.
About Resurge Therapeutics, Inc.
Resurge Therapeutics, founded by an experienced team in drug delivery and urology, is dedicated to solving unmet problems in urology through minimally invasive local drug delivery solutions. The company’s lead pipeline candidate focuses on treating lower urinary tract symptoms caused by BPH. Resurge Therapeutics combines expertise in drug delivery, medical devices, and urology to develop innovative solutions that have the potential to transform patient care.
For more information about Resurge Therapeutics and its mission, please visit https://www.resurgetherapeutics.com/.
About BPH: Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that affects many men as they age. It can cause uncomfortable urinary symptoms such as frequent urination, weak stream, and difficulty emptying the bladder. While not life-threatening, BPH can significantly impact the quality of life and may lead to complications if left untreated.
About bioaccess®: bioaccess® is a leading contract research organization (CRO) specializing in the planning and executing clinical trials for medical devices in Latin America. With extensive experience and an in-depth understanding of the regional regulatory landscape, bioaccess® is crucial in bringing innovative medical technologies to market.
###
